Role of Biotransformation Studies in Minimizing Metabolism-Related Liabilities in Drug Discovery by Shu, Yue-Zhong et al.
Review Article
Themed Issue: Enabling Drug Developability: Defining Metabolism Properties of New Drug Candidates During Drug Discovery
Guest Editors: Saeho Chong and Kenneth S. Santone
Role of Biotransformation Studies in Minimizing Metabolism-Related Liabilities
in Drug Discovery
Yue-Zhong Shu,
1,3 Benjamin M. Johnson,
1 and Tian J. Yang
2
Received 12 October 2007; accepted 13 February 2008; published online 13 March 2008
Abstract. Metabolism-related liabilities continue to be a major cause of attrition for drug candidates in
clinical development. Such problems may arise from the bioactivation of the parent compound to a
reactive metabolite capable of modifying biological materials covalently or engaging in redox-cycling
reactions leading to the formation of other toxicants. Alternatively, they may result from the formation of
a major metabolite with systemic exposure and adverse pharmacological activity. To avert such problems,
biotransformation studies are becoming increasingly important in guiding the refinement of a lead series
during drug discovery and in characterizing lead candidates prior to clinical evaluation. This article
provides an overview of the methods that are used to uncover metabolism-related liabilities in a pre-
clinical setting and offers suggestions for reducing such liabilities via the modification of structural
features that are used commonly in drug-like molecules.
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INTRODUCTION TO METABOLIC LIABILITIES
IN DRUG DISCOVERY
A major aim in drug discovery is the identification of safe
and efficacious medicines that can be administered according
to convenient once- or twice-daily dosing regimens. Since
metabolic processes influence many other parameters that are
relevant in this regard, including bioavailability, systemic
clearance and toxicology, issues relating to drug metabolism
are important in the selection of viable drug candidates.
Substantial emphasis was placed in previous decades on the
advancement of knowledge and the development of new
technologies in the areas of absorption, distribution, metab-
olism and excretion (ADME) to assist in the identification of
compounds with drug-like characteristics early in discovery.
These improvements included the widespread adoption of
animal models for the assessment of oral exposure and drug-
metabolism screening assays for the measurement of parent-
compound disappearance in liver microsomes as a proxy for
hepatic CYP activity. Recently, evidence has emerged that
these investments have paid off in helping to reduce the
number of compounds discontinued due to unacceptable
pharmacokinetic properties (1). There remains much progress
to be made, however, in reducing attrition on account of other
biotransformation-related liabilities. The identification of bio-
activation pathways that might produce toxicity and the
prediction of drug–drug interactions that might lead to
alterations in the pharmacokinetic profiles of co-administered
agents continue to be major challenges in drug discovery (2–4).
It is believed that similar technological advancements adopted
recently will allow such properties to be identified early in drug
discovery, streamlining the selection of lead candidates and
ultimately leading to the development of higher quality drugs.
Reactive Metabolites
One way that a chemically reactive metabolite may exert
adverse effects is by inactivating the same drug-metabolizing
enzyme that catalyzes its formation, a situation that applies
especially to compounds that are highly reactive or exhibit
favorable binding interactions inside the catalytic pocket.
Such an event may raise the exposure of either the parent
compound or another drug (i.e. probe substrate) that relies
on the same enzyme for clearance (5). The magnitude of the
change in exposure depends on both the inactivation kinetics
(KI, kinact, partition ratio r) and the extent of involvement of
the enzyme in the elimination of the probe substrate (6–9).
Another path to adverse effects involves the escape of the
reactive metabolite from the catalytic site. This event requires
the metabolite to be stable enough to resist both solvolysis
and covalent binding to functional groups lining the surface of
the enzyme. Reactive metabolites that leave the pocket may
react with GSH covalently or, in the case of quinoid
metabolites, lower GSH levels indirectly via the cycling of
reactive oxygen species; either scenario represents a potential
source of oxidative stress for the cell that may lead to various
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of a large amount of protein in the cell may result in
dysfunction, apoptosis or necrosis. At the organism level
these changes may manifest as acute organ toxicity, especially
hepatoxicity. Toxicities of the kidneys, lungs, adrenal glands,
and skin have also been reported in cases involving either
non-hepatic bioactivation or the transport of reactive metab-
olites through the circulatory system. Idiosyncratic adverse
drug reactions (IADRs) are another concern in regard to the
adverse effects of reactive metabolites, which may act as
haptens in conjunction with endogenous proteins (10–13). In
certain cases, oxidative stress and extensive covalent protein
binding may represent “danger signals” that exacerbate the
immunological response to these antigenic complexes and
magnify the toxicity of the reactive metabolite. Although it is
not possible using present technology to predict which
reactive metabolites will act as haptens and which will not,
it has been noted that compounds that are administered in
low doses carry a reduced risk of IADRs.
METHODS FOR THE ELUCIDATION
OF BIOTRANSFORMATION-RELATED LIABILITIES
Generally speaking, a select few possible causes have been
recognized for the onset of undesired biological effects associ-
ated with drug metabolites. One possibility is the bioactivation
of the parent compound to a reactive metabolite, which may be
capable of either modifying biological material covalently or
participating in redox-cycling reactions (14) leading to the
formation of other toxicants. Many such metabolites have been
observed to possess intermediate stability (15)o rc o m m a n d e e r
transport systems within the circulatory system (16), allowing
them to exert effects that are remote from the site of
formation. Alternatively, interactions between metabolites
and nearby drug-metabolizing enzymes may alter metabolic
clearance in a time-dependant fashion or affect the kinetics of
co-administered pharmaceutical agents. Noncovalent off-target
binding, possibly leading to adverse pharmacological events, is
an infrequent occurrence (17) but is potentially problematic for
drugs that are converted extensively to metabolites that enter
systemic circulation and/or distribute into tissues. The need to
predict such biotransformation-related liabilities, and to select
those compounds with the greatest chance of clinical success,
has led to the development of methods that can be used to
identify problematic compounds in the discovery stage. The
following section describes some of the most helpful proce-
dures that are used commonly toward this end.
In Vitro Bioactivation Studies
Trapping with Glutathione and Other Nucleophiles. Exper-
iments seeking to identify stable conjugates as surrogates for
the formation of short-lived, electrophilic metabolites have
become widely used in the pharmaceutical industry. Many
variations on these experiments have been developed over
recent years, but common elements appear to include the
addition of a low-molecular-weight nucleophile to a preparation
containing a test article and a drug-metabolizing homogenate
(e.g. liver microsomes or S9 with necessary cofactors included),
followed by an incubation period and characterization using LC-
MS-MS of any conjugates that are formed. The endogenous
tripeptide glutathione (GSH) serves as a sensible trapping agent
in this context, since it is involved in both the toxication and
detoxication of certain xenobiotics in the liver. In vitro,
concentrations of GSH in the range of 5–10 mM are often
used to mimic this hepatic environment. The selective detection
of GSH conjugates within complex mixtures is usually achieved
by positive-ion electrospray mass spectrometry and neutral-loss
scanning for components that liberate the γ-glutamyl moiety
(129 Da) of GSH, one of several groups released readily during
mass spectrometry and collision-induced dissociation (CID)
(18). Alternative screening approaches have also been
proposed. For example, the use of precursor-ion scanning for
the charged γ-glutamyl group (m/z 130) is similarly applicable
and also allows the detection of biprotonated GSH conjugates,
such as bis-glutathionyl metabolites or large-molecular-weight
GSH conjugates that typically give neutral losses of 64.5 Da
instead of 129 Da during CID (19). Also in use are several
“GSH-like” trapping agents, which are intended to retain the
nucleophilic reactivity of GSH while incorporating other
properties to facilitate analysis or quantification of the
resulting conjugates. GSH analogs that have been dansylated
(20), esterified (21), or labeled with either stable (22)o r
radioactive isotopes are all examples of these modified
trapping agents which can be analyzed readily using tandem
mass spectrometry and other techniques such as fluorescence
detection or scintillation counting.
Whereas GSH and similar thiols are broadly reactive
toward electrophilic substrates, occasionally they may be
ineffective in trapping reactive metabolites from a few select
classes. For example, the oxidation of an alkylamine may
involve a spontaneous loss of water leading to the formation
of an iminium ion that is reactive toward “hard” nucleophiles
but not toward GSH. To ensure that the potential reactivity of
these metabolites does not go unnoticed, a drug-metabolizing
system may be supplemented with a cyanide salt instead of
GSH to give conditions that are favorable for the formation
of cyano adducts (23). Because of the highly toxic nature of
solutions containing cyanide, the use of these methods
requires a strong commitment to careful handling and proper
disposal. However, even if cyanide is not added to these
solutions directly, a cyano adduct may still be observed if the
test article is pre-dissolved in acetonitrile and the enzymatic
preparation (e.g. liver microsomes) is capable of generating
small quantities of cyanide in vitro. Like a GSH adduct, a
cyano adduct may be identified readily using positive-ion
electrospray (or APCI) tandem mass spectrometry, often
exhibiting a mass gain of 25 Da over of the parent compound
and a neutral loss of HCN (27 Da) during MS/MS with CID.
In addition to the use of cyanide and GSH-related
compounds as trapping agents, the use of amines has also
been reported for the trapping of acylhalides and glyoxal
groups (3). However, screening applications where these
agents are added to liver microsomes for the trapping of
oxidation products do not appear to be used widely.
Covalent Binding. The covalent-binding experiment rep-
resents a complementary approach to measuring rates of
reactive-metabolite formation in liver microsomes, with
correlations between rates of covalent binding and GSH-
conjugate formation having begun to emerge (24). Experi-
mental procedures for this experiment, which have been
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articles that are labeled with β-emitters such as
3Ho r
14C and
are therefore substantially more resource-intensive than the
trapping experiments described above. Briefly, these test
articles (usually 10 μM) are incubated with liver microsomes
(1 mg protein/ml), NADPH, and either GSH or cyanide
(optional) for sufficient time to give the desired metabolic
turnover, and then protein is precipitated, washed and
dissolved for scintillation counting. A reduction in the level
of covalent binding in the presence of GSH or cyanide may
implicate certain structural features of the reactive inter-
mediate and provide evidence for its escape from the catalytic
site. Researchers at Merck & Co. have proposed a binding level
of 50 pmol mg protein
−1 h
−1 as a conservative threshold for an
acceptable level of covalent binding for a drug candidate. This
number was based on (a) levels of protein adducts observed in
livers following bioactivation-mediated necrosis, and (b) a 20-
fold safety margin, below which such necrosis would
presumably be unlikely (25). Although Merck has reported
some success in using this approach to identify problematic
compounds in its discovery efforts, both the cost–benefit
relationship of maintaining a radiosynthesis group to support
covalent-binding studies and the utility of the 50 pmol mg
−1 h
−1
threshold in deciding whether to advance compounds into
development continue to be topics of debate in the greater
drug-metabolism community. On the latter point, additional
considerations might provide a context for evaluating the
potential liability associated with elevated levels of covalent
binding, such as the potential for bioactivation in vivo,t h e
clinical indication and dose, and the availability of preliminary
toxicological findings.
Mechanism-Based CYP Inhibition. During multi-drug
therapy, a therapeutic agent that is also an inhibitor of a
CYP (or other drug metabolizing enzyme) may have the
potential to affect the pharmacokinetics of co-administered
agents that rely on the same enzyme for metabolic clearance
(26). Hence, inhibitors of CYP3A and other enzymes that are
involved in the clearance of a wide variety of substrates are
usually flagged in drug discovery and precluded from
advancement into development. Biotransformation studies
may play a role in the identification of such compounds in
certain cases. For example, the formation of a reactive
metabolite may lead to the covalent modification the same
CYP enzyme involved in catalysis, leading to irreversible
inhibition of the enzyme (27). Such behavior can usually be
attributed to chemical structures that also have a proclivity
toward bioactivation and the formation of GSH and protein
conjugates (e.g. alkynes, thiophenes, halogenated alkenes)
(28). However, the presence of GSH may fail to prevent the
onset of irreversible inhibition, since binding may occur
before the substrate has a chance to leave the active site. A
separate set of experiments is therefore necessary to deter-
mine whether a compound of interest may carry the liability
of mechanism-based inhibition.
Studies to evaluate mechanism-based CYP inhibition
usually involve pre-incubation of a test article (at multiple
concentrations) in liver microsomes or recombinant CYPs,
with and without NADPH, followed by the addition of a
probe substrate whose rate of disappearance is then mea-
sured. Midazolam and testosterone are common probe
substrates used to evaluate effects on CYP3A4. Test articles
that reduce the rate of consumption of the probe substrate
with respect to the control that is pre-incubated without
NADPH are usually studied further. For example, dialysis
experiments can be used to investigate the restoration of CYP
activity following removal of unbound material, or spectro-
photometric studies of CYP structure can be used to
determine whether the hemeprotein has been modified.
Methods for these studies have been described (29–32).
Reactivity and Rearrangement of Acyl Glucuronides. The
formation of acyl glucuronides is a matter of concern in
biotransformation studies on account of the potential for
these metabolites to react covalently with other biological
molecules including proteins. These reactions have been
implicated in severe toxicity, resulting in the withdrawal of
multiple drugs from the marketplace in the USA and other
countries (33). In the reaction of acyl glucuronides with
nucleophilic substrates, the sugar moieties of O-1-acyl glucur-
onides may either be displaced directly by nucleophilic amino
acids or may first undergo acyl migration to O-n-acyl
derivatives, where n may correspond to carbon atoms 2, 3,
or 4 of the glucuronide moiety. In recent years, methods have
been introduced to monitor the kinetics of these processes
and to allow comparisons among acyl glucuronides with
respect to reactivity. As a caveat it should be noted that direct
relationships between the reactivity of acyl glucuronides and
the severity of organ toxicity have not been demonstrated.
One approach in the assessment of acyl-glucuronide
reactivity involves the trapping of an activated sugar moiety
with a protein surrogate. For example, the Lys-Phe dipeptide
has been shown to react with rearranged acyl glucuronides
via Schiff base formation (34). The rates of these reactions
appear to correlate well with those of acyl migration,
suggesting that acyl glucuronides that undergo rearrangement
are more reactive toward Lys-Phe than those retaining their
original O-1-acyl connectivity. Hence, this technique could be
applied to rank-order compounds within a chemical series
based on the reactivity of their respective acyl-glucuronide
conjugates. NMR spectrometric methods have also been
introduced to monitor the stability of acyl glucuronides and
elucidate the structures of their degradation products (35–37).
The former task is accomplished in part by analyzing the
resonance signals associated with the anomeric proton of the
O-1-acyl glucuronide as a function of time. As would be
expected, the disappearance of these signals follows first-
order kinetics, allowing the calculation of a t1=2 as a measure
of reactivity. Additional information about the structures of
rearranged products is also available by inspection of the
NMR data following an extended incubation period.
Biotransformation Modeling in Silico
The identification of metabolites is a resource-intensive
process, both in terms of the time required to carry out
biotransformation studies and the need for the scientist who
interprets the LC-MS/MS data to be highly trained. This leads
to both human and instrumental biases, especially in cases
where metabolites are not radiolabeled and are hidden within
complex biological matrices that may suppress ionization or
180 Shu, Johnson and Yangcontain isobaric interferences. In order to accelerate metab-
olite identification and provide a check against these biases
that might cause unusual or low-level metabolites to be
overlooked, informatics tools have been developed for data
mining and interpretation. Anari and co-workers described
the metabolic profiling of indinavir with an approach
combining data-dependent LC-MS/MS and knowledge-based
metabolite predictions that were generated using a substruc-
ture similarity search of the MDL Metabolite Database (38).
Several other programs have been developed for this purpose
(39–44), including an approach co-developed at Bristol-Myers
Squibb for LC-MS/MS data mining of potential metabolites.
As shown in Fig. 1, the tool named “Metabolite Profiler”
combines a comprehensive collection of metabolic modifica-
tions (reaction table) with structure-specific metabolite pre-
dictions using METEOR (Lhasa Ltd) (45). The Profiler
calculates the molecular masses of predicted metabolites,
removes duplicates, and automatically generates a result file
that can be imported into data-analysis programs (e.g. Met-
Works). The imported result file is then used to generate
customized extracted-ion chromatograms for data mining and
identification of potential metabolites based on anticipated
mass-to-charge ratios. This routine has been incorporated
into the workflow for biotransformation studies, proving to be
useful in broadening the coverage of potential metabolites
and providing a check against human and instrument-related
biases.
Animal Models and the Study of Metabolic Fate
Use of Mechanism-Based Inhibitors in the Elucidation of
Toxicological Mechanisms. Whereas mechanism-based
inhibitors are usually avoided in multi-drug therapy for the
reasons described above, they can be useful tools in
determining whether a toxicological event in vivo is the
result of exposure to a compound or its metabolites. The
suicide inhibitor 1-aminobenzotriazole (ABT) is the most
widely used tool in this regard. ABT undergoes bioactivation
to a reactive intermediate that alkylates most CYPs, resulting
in their inactivation (46). Thus, the pretreatment of animals
with ABT during a toxicology study (a dose of 50 mg/kg
administered 2 h before administration of the test article is a
common practice (47,48)) may reduce the severity of adverse
events, but only if such events are mediated by a toxic
metabolite and not the parent compound itself. This approach
has been used to implicate metabolites in the onset of
hepatotoxicity in mice following administration of furosemide,
(49) and nephrotoxicity in rats following treatment with
[2,3-
14C]-N-(3,5-dichlorophenyl)succinimide (50). In both of
these cases, toxicity of the target organ correlated positively
with covalent binding and was reduced in animals pretreated
with ABT.
Absorption, Distribution, Metabolism and Elimination
(ADME) Studies Using Bile-Duct-Cannulated Animals. The
characterization of promising compounds in drug discovery
usually includes a series of studies to ascertain the main
metabolicanddispositionpathwaysinanimals.Whentheresults
of these studies are considered alongside in vitro biotransfor-
mation data, some initial predictions can be made as to which
clearance pathways might be the most important clinically, and
which metabolites detected in human liver microsomes (or
hepatocytes) will also be represented during toxicological
assessments in animals. These predictions can help prepare
an organization for upcoming non-clinical toxicology studies
during drug development, in light of FDA guidelines for the
evaluation of metabolites in drug safety (51).
Biotransformation studies using bile-duct-cannulated
(BDC) animals are advantageous in this regard, allowing
metabolic profiling across species and offering insight into the
extent of formation in vivo of metabolites of interest, such as
GSH conjugates or acyl glucuronides, which may indicate
bioactivation (52). Studies in BDC animals can also provide
information on mass balance, absorption, tissue distribution,
or elimination of a drug, depending on study design. Mass
balance is obtained typically by dosing
14C-labeled compound
and then quantifying radioactivity present in bile, urine, and
feces over a collection interval of sufficient length to allow
extensive elimination of the drug and its metabolites (53).
Radioactivity remaining in the tissues following the collection
interval can also be quantified either via combustion and
liquid-scintillation counting of individual organs or using
whole-body autoluminography. Although studies using
radioactive test articles are typically carried out with the aim
of recovering high percentages of the doses administered,
there are differing perspectives within the industry as to what
criteria are most useful in deciding whether a study has
fulfilled its objectives and whether studies achieving only
moderate recovery should be repeated (54).
The design of a study using BDC animals, with
consideration given to routes of administration and the
selection of proper controls, determines which of the ADME
parameters can be estimated in the interpretation of the data.
For example, a comparison of plasma concentrations in two
groups dosed via portal-vein infusion and intravenous infu-
sion, respectively, provides an estimate of hepatic extraction
Fig. 1. Procedure for the identification of metabolites using Metabolite Profiler
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following oral and intravenous dosing provides information
on the extent of absorption from the gastrointestinal tract and
the possible involvement of P-glycoprotein and other trans-
porters in disposition. Similarly, differential absorption in
BDC and non-cannulated animals can help distinguish
between enterohepatic recirculation and discontinuous ab-
sorption as possible causes for inflections in plasma concen-
trations over time, as illuminated during pharmacokinetics
studies. It is therefore important to consider the questions to
be answered during such a study before selecting methods for
the administration of the test article.
Covalent Binding in Vivo. In addition to the methods
described above pertaining to covalent-binding experiments in
vitro, similar experiments have been described to characterize
binding levels in animals. In both cases, compounds labeled
with
14C are the substrates of choice because they do not
experience losses of radioactivity in solution, as is sometimes
the case with
3H tracers. However, it is still important to
install the
14C label in a position that does not undergo
metabolism; thus, biotransformation studies are often carried
out in advance to characterize metabolic pathways in the
animal of interest before labeled-compound synthesis is
undertaken. To prepare samples, animals are dosed with
radioactive compound, sacrificed after a time based on
pharmacokinetic parameters, and the organs of interest are
removed. These organs usually include the liver, where
concentrations of CYPs and other drug-metabolizing
systems are high, although marginal levels of binding in
other organs such as lung and kidney have also been reported
(55). Following homogenization of these organs and
centrifugation into subcellular fractions, the methods used
for the washing of protein and the counting of radioactivity
resemble those used during covalent-binding studies in vitro.
Distribution Studies Using Mass Spectrometric Imaging.
Recent advances in matrix-assisted laser desorption/ioniza-
tion mass spectrometry (MALDI-MS) have enabled the
creation of “maps” showing the spatial distribution of drugs
and their metabolites in tissue sections of either organs or
whole animals. This technique has certain advantages over
whole-body autoradiography, since it can be performed using
a non-radiolabeled drug and has the capacity to distinguish
among drug-related compounds based on mass-to-charge
ratios. Potentially, this latter feature allows for the creation
of a separate map for the distribution of each metabolite in a
mouse or other small animal. Furthermore, a linear relation-
ship between the concentration of a compound in a sample
and the intensity of a MALDI-MS signal can be defined over
a wide dynamic range, allowing quantitative information to
be obtained on any ionizable analyte (parent compound,
metabolite, or endogenous component) for which a synthetic
standard is also available. This is a particularly useful tool in
addressing situations where a metabolite is known to have an
effect on a particular organ or substructure (e.g. a seizuro-
genic metabolite in the brain, an ion-channel inhibitor in the
heart, etc.), providing information on the distribution and
concentration of the compound within the organ of interest.
Review articles and other useful descriptions of MALDI-MS
imaging are available in the literature (56–58).
Genetic Modification
Emerging techniques such as RNA interference (RNAi)
and the use of genetically modified (e.g. knockout, transgenic)
animals are being applied increasingly in the study of drug
metabolism. RNAi can be used to knock down the expression
of a gene for a drug-metabolizing enzyme or transporter in a
post-transcriptional manner, allowing the role of such proteins
in the metabolism of a xenobiotic substrate to be characterized
specifically (59). During drug discovery and development, this
technique may be particularly useful in helping to resolve a
toxicological issue by allowing an adverse event in an animal
to be ascribed to a species-specific structure or process.
Although few such examples have been published, a similar
approachwasusedrecentlytoshowthatknockdownofthegene
encoding the α-synuclein protein resulted in the protection of
human neurons against the neurotoxin MPP
+ (60). Animals
that are engineered to express specific human proteins are also
under development in an attempt to produce models that
facilitate more accurate predictions of human metabolism.
Reviews of this topic are available in the literature (61,62).
MOLECULAR DESIGN AND THE AVOIDANCE
OF METABOLISM-RELATED LIABILITIES
The failure of drug candidates can often be attributed to
the toxicological effects of particular functional groups that
undergo bioactivation; thus, reactive metabolites are general-
ly considered within the pharmaceutical community to
represent potential liabilities in the development of a drug.
Recently, increasing emphasis has been placed on the
detection and identification of chemical markers of bioacti-
vation, including GSH conjugates, and this effort has been
assisted by improvements in the sensitivity and selectivity of
spectrometric instrumentation. As a result, many structurally
diverse and unusual GSH conjugates have been identified
despite relatively low quantities in biologic matrices. Most of
the bioactivation sequences leading to these metabolites can
be rationalized in the context of basic CYP-mediated
oxidations and rearrangements, some of which are affected
by neighboring or sterically proximal functional groups in the
substrate molecule.
When a reactive metabolite is found, an investigation of
the underlying bioactivation mechanism may lead to a more
complete understanding of the potential metabolic liability.
Often these studies lead to the identification of problematic
structural features to be avoided in the evolution of a lead
series, such as those summarized in Fig. 2 that lead to the
formation of GSH or cyanide adducts. In light of the increas-
ingly large volume of literature in this area, including review
articles that cover related topics (3,25,63), this section is
intended to be illustrative rather than comprehensive, and the
structure types to be discussed are limited primarily to drug-
like molecules. As a point of differentiation from published
reviews, this section also focuses on strategies to avert
bioactivation in certain chemical series by suggesting appro-
priate substitutions to functional groups in representative
compounds. This approach to drug discovery extends the
concept of bioisosteric replacement beyond its typical appli-
cation in optimizing the physicochemical properties and
biological activities of test compounds, and it requires a close
182 Shu, Johnson and Yangpartnership between biotransformation scientists and medic-
inal chemists in managing the evolution of a chemical series.
Amines and Azacycles
Cyclic and acyclic secondary and tertiary amines and
azacycles are used widely as functional groups in drug-like
molecules despite a proclivity toward bioactivation to elec-
trophilic iminium ions and/or carbinolamines. These two
types of electrophiles may have distinct mechanisms of
formation but are usually assumed to co-exist with each other
in a hydrolytic equilibrium. Decomposition of these products
via N-dealkylation is a possibility that may lead to the
elimination of the carbinol-bearing moiety and sometimes to
intra-molecular rearrangement. Alternatively, there is evi-
dence that iminium ions from nitrogen-bearing heterocycles
may be oxidized further to stable lactams in the presence of
cytosolic aldehyde oxidases. The reactivity of iminium ions
toward GSH is sometimes obscured by the instability of the
resulting conjugate under laboratory conditions; thus, a
cyanide salt is often used to supplement microsomal prepa-
rations such that they may be trapped as meta-stable cyano
Fig. 2. Common bioactivation pathways leading to glutathione or cyanide adducts
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iminium ions might react with nucleophilic sites within
cellular macromolecules and contribute to the pharmacology
or toxicology of aliphatic amines (64).
The alkylation of DNA by imines has been implicated in
the antitumor pharmacology of multiple DNA-acting cyto-
toxic natural products, including ecteinascidin 743 (65),
cyanocycline (66), doxorubicin (67) and barminomycin (68).
The corresponding imines, accessible either directly or via
bioactivation, have been reported to react covalently with
DNA in a base-specific manner. (Fig. 3).
Extensive metabolic, biochemical, and toxicological
investigations have established that the neurodegenerative
properties of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP; Fig. 4) are mediated in a tissue-
selective manner by the pyridinium metabolite MPP
+,a
product of catalysis by monoamine oxidase B. Whereas
covalent binding with macromolecules is not implicated
directly, MPP
+ selectively inhibits the activity of complex I
of the mitochondrial electron transport chain. The depletion
of ATP that follows from this inhibition is considered to be
the principal cause of cell death.
Multiple cyclic amines, such as N-benzylcyclopropyl-
amine, phencyclidine, and (S)-nicotine (Fig. 4) were reported
to undergo bioactivation to iminium intermediates, a pathway
associated with covalent binding to macromolecules. Covalent
binding during the metabolism of (S)-nicotine is reduced by
cyanide, and studies have shown that N-benzylcyclopropylamine
and phencyclidine cause CYP inactivation during metabolism.
The iminium metabolite of N-benzylcyclopropylamine inacti-
vates these enzymes by covalent modification of the active
site, whereas phencyclidine is not classified as a mechanism-
based inactivator since its reactive intermediate is believed to
escape the active site.
Pyrrolizidine alkaloids (PAs) such as reddiline, which
occur naturally in flowering plants from the Boraginaceae,
Compositae and Leguminosae families, have been shown to
be genotoxic and tumorigenic in experimental animals. CYP-
catalyzed N-oxidation of these compounds results in the
formation of non-toxic metabolites that are highly polar and
easily excreted. However, CYP also catalyzes dehydrogena-
tion to unstable pyrroles that may undergo further O-
dealkylation to give DHP (69) (Fig. 4). Both DHP and the
PA pyrroles can react with DNA and other macromolecules
via the formation of carbonium intermediates (70). Since
these intermediates are highly reactive, their effects in vivo
are usually confined to the site of formation in the liver and
other CYP-expressing tissues. Thus, hepatotoxicity is the
most prominent effect of PA administration in animals.
The structural modification of amines that are prone to
bioactivation generally focuses on attenuating the extent of
formation of the iminium species. Lowering the substitution
on the nitrogen atom, for example replacing a tertiary amine
with a secondary amine, usually stabilizes the nitrogen against
electron abstraction by raising the energy of the transition
state en route to the radical intermediate. The nitrogen can
also be stabilized against CYP-mediated metabolism by
introducing steric hindrance on functional groups nearby or
installing alkyl or halogen groups at the α-o rβ- carbons. In
the case of 5- or 6-membered cyclic amines, it may also be
helpful to fuse these structures into heterocycles or reduce
the number of atoms in the ring (e.g. replace a pyrrolidine
ring with an azetidine moiety) to overcome a metabolic
liability (Fig. 5).
Fig. 3. Examples of cytotoxic natural products that form DNA adducts via imine or iminium intermediates
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rated into a drug-discovery workflow were provided recently.
In one such case, a piperazine-containing compound had
been deemed unviable as a drug candidate because of high
covalent binding (~300 pmol eq/mg protein) and time-
dependent CYP3A4 inactivation in human liver microsomes.
However, structural modifications to its lactam- and α,α′-
dimethyl-substituted derivatives were employed to minimize
oxidation of the piperazine nitrogen and the formation of a
reactive iminium moiety, giving rise to new analogs that
avoided these liabilities (71). In another case, the discovery of
sitagliptin, a dipeptidyl peptidase IV (DPP-4) inhibitor, was
facilitated by structural modifications to a series of pipera-
zine-containing compounds that resulted in lower metabolic
clearance. In order to reduce the level of oxidative metabolism
among early DPP-4 inhibitors containing the piperazine,
bicyclic derivatives including imidazolopiperazines and triazo-
lopiperazines were prepared and evaluated in various metab-
olism models, including BDC animals. This iterative lead
optimization effort yielded improvements in the oral bioavail-
ability of newer compounds and ultimately led to the discovery
of sitagliptan, which was selected from the triazolopiperazine
series for further development and was approved by the US
FDA in 2006 for the treatment of type 2 diabetes (72).
Aromatics
Arylamines or anilines have long been associated with
chemical carcinogenesis, and reports have indicated that the
genotoxicity of arylamines is tied to metabolic activation,
proceeding initially by N-hydroxylation of the primary amine
Fig. 4. Examples of secondary and tertiary amines that undergo
bioactivation
Fig. 5. Bioisosteric alternatives to selected functional groups
185 Minimizing Metabolism-related Liabilities in Drug Discovery(73,74). The reactive N-hydroxylamine metabolites can either
undergo oxidation to more reactive nitroso intermediates or
conjugations to N-O-sulfates or N-O-acetates, effective leav-
ing groups that may lead to highly reactive nitrenium ions.
Due to heightened awareness of the potential genotoxicity of
arylamines, unprotected and oxidizable primary arylamines
are not deemed to be drug-like and are rarely seen in today’s
drug candidates. However, latent arylamines that are chemi-
cally masked and not subject to oxidation are still used as
core scaffolds in medicinal chemistry. In drug development,
the potential metabolic release of a mutagenic free arylamine
remains a concern for human safety, and health regulators
may require monitoring of released arylamine in humans
using sensitive LC-MS-MS methods, posing a hurdle to
regulatory approval. Thus, it is important to assess and
minimize the formation of such genotoxic metabolites before
a clinical candidate is selected. To this end, non-mutagenic
arylamines may be adopted as surrogates for anilines. Among
masked arylamines, the risk of releasing free arylamine during
hydrolytic or oxidative metabolism is largely related to the
stability of the bond connecting the arylamine moiety to the
rest of the molecule (Fig. 6). Additional synthetic strategies
may therefore focus on forming a metabolically stable linkage
while retaining any desired activity.
The potential metabolic formation of ortho or para-
aminophenols from masked arylamines also represents a
structure alert (Fig. 2), as they could be oxidized subsequently
to quinone imines. A strategy to avert the formation of such
electrophilic intermediates is to introduce electron-withdraw-
ing groups into the ring system to block the oxidation site
directly or reduce the overall electron density of the ring. As
a caveat, oxidative dehalogenation has been noted during the
metabolism of certain halogen-substituted aromatics, such as
hexachlorobenzene (75), voriconazole (76), and DPC 963
(77) (Fig. 7), and some of these compounds go on to form
GSH conjugates. The oxidations are catalyzed by CYP and
may proceed either by ipso attack and sigma complex
formation, or via the formation of an arene oxide (with or
without an NIH shift involving the halogen atom) followed by
elimination (Fig. 2)( 75,76). Although the occurrence of CYP-
mediated oxidations of halogenated phenyls may seem at
odds with the electron-withdrawing effects of halogens, this
reactivity may be attributable to the mesomeric properties of
halogen atoms rather than their electron-withdrawing effects.
Additionally, aromatic halogenation often leads to increased
lipophilicity, which may augment both tissue penetration and
affinity for the CYP catalytic site. Thus, the metabolism of
halogenated aromatics depends on multiple factors and is
difficult to predict.
π-Rich and Related Five-Membered Heterocycles
Five-membered π-rich heterocycles such as pyrroles,
furans, thiophenes, and their benzo-fused derivatives are
widely used in drug molecules. These electron rich systems
share a common electronic property, with six electrons
distributed over five atoms, and undergo many metabolic
reactions leading to both stable and reactive metabolites
(Fig. 2). A multitude of related biotransformations on 5-
membered heterocycles (78) and implications for potential
toxicity (3) were reviewed recently and will not be discussed
further. Compared to pyrroles, furans and thiophenes, ring
systems containing an additional nitrogen atom such as azoles
and isoazoles share the common characteristics of reduced π-
electron density and a new site of basicity. Both of these
properties can affect their metabolism. The placement of the
nitrogen atom within the ring is also important. For example,
imidazoles, oxazoles, and thiazoles are susceptible to oxida-
tive metabolism and sometimes bioactivation, whereas iso-
xazoles and isothiazoles undergo reductive ring cleavage,
sometimes by non-CYP enzymes. By contrast, pyrazole rings
are relatively stable to either oxidative or reductive metabo-
lism despite the presence of an isoazole linkage (78). Five-
membered heterocyles containing three or more heteroatoms,
such as triazoles and oxadiazoles, have even less π-electron
density than azoles and are also resistant to CYP-mediated
oxidations. However, non-CYP mediated or mixed-mode
pathways may present alternative routes of biotransformation
for these compounds and lead to ring-scission products (78).
The bioactivation of 5-membered heterocycles with two or
more heteroatoms is difficult to generalize, and the assess-
ment of their metabolic liabilities remains chemotype-,
compound-, or even substitution-specific. Still, these hetero-
cycles are widely used as bioisosteres for esters and amides
and may offer vastly improved metabolic stability over such
non-cyclic counterparts. A known metabolic liability of some
pyrazoles, imidazoles and triazoles is heme coordination
inside the CYP catalytic pocket. Known as type-II ligands,
these compounds can inhibit CYP by replacing the heme-
water ligand and stabilizing the iron in its low-spin state (79–
81). Certain alkyl-substituted heterocycles may be metabo-
lized to imine-methide-like intermediates that alkylate the
CYP active site, resulting in enzyme inactivation (82). The
formation of type-II complexes may inhibit the metabolism of
co-administered drugs and result in drug–drug interactions;
thus, compounds capable of forming these complexes must be
tested for CYP inhibition early in drug discovery.
Six-Membered Heterocycles
It is difficult to predict bioactivation reactions on 6-
membered heterocyles because of the widely variant elec-
tronic and steric effects of ring substituents. The reader is
Fig. 6. Masked arylamine linkages and relative risk for enzyme-
mediated arylamine release
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examples of bioactivation of such structures (3). Phenol rings
containing o-o rp-substituted electron-donating substituents
such as alkyl groups or amines are susceptible to the formation
of quinoid metabolites that can act as Michael acceptors in the
alkylation of cellular proteins and DNA. Electron-withdrawing
substituents usually deactivate hydroquinones and cause them
to be less easily oxidized, whereas the opposite is true for
electron-donating groups. This observation has two important
consequences: first, quinones, quinone imines, and quinone
methides are successively easier to oxidize because electroneg-
ativity decreases in the order O>N>C (83), and second, the
conjugation of quinones with GSH and other thiols cannot
generally be viewed as a detoxication step, since the thioether
is itself electron-donating and may facilitate redox cycling or
covalent reactivity (84–88). The redox cycle between a quinone
and hydroquinone triggers the formation of reactive oxygen
species (ROS) such as superoxide, hydrogen peroxide and the
hydroxyl radical, leading to cellular damage and oxidative
stress (89–91). A structural alert for bioactivation vulnerability
is the combination of a 6-membered heterocycle, and some
combination of alkyl, amino, or hydroxyl substituents that are
situated ortho or para to each other. As a structural
requirement, the alkyl group must contain either a hydrogen
atom or suitable leaving group on the benzylic carbon atom.
The hydroxyl group is then installed metabolically, either
introduced by hydroxylation or unveiled via O-dealkylation or
hydrolysis. For example, the bioactivation of the antibacterial
agent trimethoprim is mediated through a pyrimidine imino-
quinone methide, which can be trapped in the presence of N-
acetylcysteine (Fig. 8)( 92).
Characterization of metabolites of a pyrazinone-containing
thrombin inhibitor revealed extensive bioactivation of the
pyrazinone ring system and high levels of irreversibly bound
radioactivityto proteinsinratsafteradministrationof
14C-labeled
drug (93). Metabolism of this compound in GSH-fortified liver
microsomes gave two conjugates derived respectively from an
imine methide and an epoxide of the pyrazinone ring (Fig. 8),
the latter facilitating opening of the pyrazinone ring and
subsequent rearrangements. Thus, pyrazinones may undergo
bioactivation along multiple pathways.
Nucleophilic Substitution Involving Glutathione
Suitably substituted heterocyclic rings that contain aro-
matic nitrogens, such as 2- or 6-halopyridines, are susceptible
to attack by GSH and other nucleophiles due to an activated
halogen–carbon bond that leaves a partial positive charge on
the carbon. In biological systems these reactions may be
facilitated by glutathione S-transferases (Fig. 9). For example,
the insecticide chlorpyrifos is metabolized by GSH-dependent
substitution of the 6-chlorine on the pyridine moiety, as
evidenced by abundant cysteine and mercapturate conjugates
in the urine of an individual who was intoxicated acutely with
this compound (94). Pyridines substituted with 2-sulfonamides
may behave similarly in this regard, as the HIV-1 protease
inhibitor PNU-109112 is metabolized by GST-catalyzed
displacement of the sulfonamide moiety. Structure–activity
studies with a variety of sulfonamides have indicated that
cleavage is assisted by an electrophilic center alpha to the
sulfonyl group such as a carbon atom bearing an electron-
withdrawing substituent (95,96)( F i g .9). Similar nonenzymatic
nucleophilic displacements of C2-substituted sulfonamides
were observed on thiazoles, benzothiazoles, 1,3,4-thiadiazoles,
and 1,3,4-oxodiazole rings under simulated physiological con-
ditions (97,98). The electrophilic C2 imine carbon and the
presence of a good leaving group, such as a sulfonamide, are
structural prerequisites for the displacement to occur (Fig. 9).
Fig. 7. Examples of aromatic dehalogenations
Fig. 8. Bioactivation of 6-membered heterocycles
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The epoxidation of olefins is a well known bioactivation
pathway, as reactive products have been demonstrated to
mediate toxicity via reaction with nucleophilic groups in
macromolecules. The reactivity of these products is enhanced
via 1,2- or 1,4-Michael addition if the olefin is a part of an
α,β-unsaturated carbonyl system (3,25,63). Various bioisos-
teres are used to mimic the spatial arrangement, electronic
properties, and other physicochemical properties of these
groups while retarding bioactivation. For example, the olefin
could be replaced by a cyclopropyl group at the expense of a
minor conformational change, or the carbonyl could be
replaced with another group (e.g. difluoromethyl) whose
inductive properties might limit oxidation of the olefin. These
options are illustrated in Fig. 5.
Metabolic Liabilities of Non-GSH Conjugates and Associated
Intermediates
Drug candidates that contain hydroxyl groups are prone
to metabolic clearance via glucuronidation and sulfation, and,
as a result, these compounds have relatively short durations
of action and poor pharmacokinetics properties in vivo. The
rate of conjugation depends on many factors and is related
directly to the nucleophilicity of the phenolate. If the phenol
is not required for activity and its nucleophilic character is not
readily removed, then several options are available to
improve metabolic stability while retaining the essential
physicochemical properties of the molecule. Whereas an
initial approach might be to replace the hydroxyl group with
a methoxyl or other alkoxyl group, this substitution would be
accompanied by a loss of H-bonding activity and may
introduce unfavorable receptor interactions and/or an addi-
tional soft spot for CYP enzymes. To avoid these problems, a
more common solution is to use an alkylsulfonamide as a
bioisostere of the hydroxyl group, or a nitrogen-containing
heterocycle (e.g. benzimidazolone, indole or indolone) in
place of the entire phenol moiety (99) (Fig. 5). The NH
moieties of these isosteres are comparable to phenols as both
Brønsted acids and H-bond donors and are not typical
substrates for conjugation reactions during biotransformation.
Acyl glucuronides are identified increasingly as electro-
philic intermediates capable of three reactions: intramolecular
rearrangement, hydrolysis, and intermolecular transacylation
with proteins leading to covalent adducts. Although several
studies have been conducted to describe these processes in
vitro, most have used experimental conditions designed to
amplify bioactivation. The view that reactive acyl glucuro-
nides may initiate toxicological or immune responses is widely
believed to be plausible but also relies heavily on circum-
stantial evidence (100). To reduce the risk of metabolism-
related liabilities associated with acyl glucuronides, tetrazoles
are often used to replace carboxylates. Tetrazoles are ionized
at neutral pH and exhibit a planar structure, similar to
carboxylates, but are also more permeable to membranes on
account of improved lipophilicity (101). Amides, imides, and
sulfonamides have also been explored as bioisosteric replace-
ments for carboxylates (Fig. 5). Since the sulfonamide,
acylsulfonamide, and sulfonylurea groups contain electron-
withdrawing groups in proximity to a nitrogen atom, these
isosteres are comparable to carboxylates in terms of acidity
but have no potential to form acyl glucuronides. Additionally,
these acid surrogates may offer a new tether for the synthetic
modulation of pharmacological and/or pharmacokinetic prop-
erties (102,103).
Several compounds are known to be metabolized to
chemically reactive intermediates via O-sulfation. The insta-
bility of these compounds arises from the ability of the sulfate
to act as a leaving group, facilitating SN1 via the formation of
Fig. 9. Nucleophilic aromatic substitutions involving glutathione
Fig. 10. Bioactivation of safrole via an unstable sulfate intermediate
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sulfation is important in the activation of the toxicants safrole,
2′,3′-estragole, and 6-hydroxymethylbenzo[a]pyrene (Fig. 10),
and that sulfotransferase (SULT) inhibitors reduce the
formation of macromolecular adducts (104). Studies using
recombinant SULTs have demonstrated that bioactivation is
usually mediated selectively by an individual SULT form.
Bioactivation by SULTs also has a cyclic nature, since the
reaction of a sulfuric acid ester with water may regenerate the
hydroxyl precursor and feed a new cycle of activation (105).
However, since the cofactor 3′-phosphoadenosyl-5′-phospho-
sulfate (PAPS) is depleted in cells more readily than uridine-5′-
diphosphate glucuronic acid (UDPGA), consumption of PAPS
may eventually end this cycle and divert the metabolism of
SULT substrates toward other biotransformation pathways.
Until recently, studies of the toxicological effects associated
with sulfate metabolites required such metabolites to be
synthesized and tested separately, and were often confounded
by the poor permeability of sulfate conjugates toward cell
membranes. However, the heterologous expression of SULTs in
cellular systems used during mutagenicity tests may represent a
useful approach in resolving such experimental issues (105).
CONCLUSION
The successful integration of biotransformation studies
into a drug-discovery workflow requires a few important
elements. The first is a concerted effort between drug
metabolism and medicinal chemistry groups to identify
metabolism-related liabilities of key compounds in a timely
manner, and to use this information effectively in managing
the evolution of a lead series. The second is a willingness to
continually evolve these practices in accordance with chang-
ing regulatory requirements, technological improvements,
and the growing body of knowledge that lies at the interface
between drug metabolism and toxicology. For the reasons
outlined in this article, this dynamic paradigm is expected to
assist in the advancement of drug candidates with a lower
probability of metabolism-related liabilities and commensurate-
ly improved chances for success in the clinic. Ultimately, it is
hoped that these changes will expedite the delivery of effective
and safe new medicines to the patients who need them.
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